現階段免疫治療為癌症的研究重要方向之一，主要都是利用人體自身的細胞來對抗癌症。免疫檢查點抑制劑屬於藥物型的免疫治療，目前在黑色素瘤及肺癌已經可以看到治療的成效，當藥物成功時，T細包不會被抑制生長，可以有效攻擊癌症細胞。在本研究中，藉由免疫細胞是能增生及遷移至癌症細胞內部，建立一個測試藥物的模型。且一改過去生物微流體晶片大多是利用平面二維的細胞培養作為基準進行藥物測試，為了更符合實際上人體內的三圍組織結構，本研究結合了組織工程上更接近真實人體的三維組織結構和微流體的全方位系統晶片，此兩種概念與技術的結合創造一個三維組織藥物檢測模型的微系統晶片。
利用微機電技術製作一微流體晶片，結合具有生物相容性的多孔隙光固化水膠材料：gelatin methacrylate(GelMA)作為細胞的支架。將肺癌細胞培養在支架上，模擬人體內的肺癌腫瘤，成功觀察免疫細胞遷移至立體的肺癌組織內部，並將遷移結果用亮度與距離關係進行分析。微流體晶片上亦有設計微柱體的結構，使水膠可以固定在晶片中。除此之外也設計濃度梯度產生器，使微流體晶片能產生0%、50%及100%三種濃度的藥物測試，藉三者的相對結果來測試藥物的成效。

Cancer immunotherapy is the artificial stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight cancer. Checkpoints inhibitors become one of the most promising ways to activate therapeutic anti-tumor immunity and have made significant breakthroughs in melanoma and lung cancer.
In this research, we established a predictive model based on T cell expression at the invasive margin to test checkpoint inhibitors. In addition, the most recent research studies taking advantage of bio-microfluidics for drug testing focus on two-dimensional (2D) cell cultures. In reality, tissue and organs are three-dimensional (3D) structures in our bodies. To approach the biomimetic situation in vitro, this study takes advantage of microfluidic techniques and tissue engineering to build a 3D drug-testing microsystem. We used MEMS technology to fabricated a microfluidic chip model and combined with highly biocompatible porous photo-initiated cross-linked hydrogel, gelatin methacrylate (GelMA), was used as a scaffold material. The lung cancer cells are cultured on a scaffold to simulate lung cancer tumors in the human body. Therefore, we can build an immunoassay system and observe the T cell migration on the three-dimensional structure. We fabricated a series of micro-pillar to allow hydrogels forming a diffusion scaffold and fixing to chamber. Also, the microfluidic chip can produce three different concentrations of drug by using the concentration gradient generator

[1] 王曉齋, "Delete Cancer.", 力京文化, Jul 18, 2015
[2] K. W. Thomas, "Patient education: Lung cancer risks, symptoms, and diagnosis. ", Up to Date , Jul 15 2019
[3] S. N. Bhayia, M. L. Yarmush, and M. Toner, "Controlling cell interactions by
micropatterning in co-cultures: Hepatocytes and 3T3 fibroblasts," Journal of
Biomedical Materials Research: An Official Journal of The Society for Biomaterials and The Japanese Society for Biomaterials, vol. 34, no. 2, pp. 189-199, 1997.
[4] J. El-Ali, P. K. Sorger, and K. F. Jensen, "Cells on chips," Nature, vol. 442, no. 7101, pp. 403-11, Jul 27, 2006.
[5] K. Bhadriraju and C. S. Chen, "Engineering cellular microenvironments to improve cell-based drug testing," Drug discovery today, vol. 7, no. 11, pp. 612-620, 2002.
[6] Y. Sun, Z. Li, J. Li, J. Han." A Healthy Dietary Pattern Reduces Lung Cancer Risk: A Systematic Review and Meta-Analysis." Nutrients, 2016
[7] R. Nell, "What to know about lung cancer?", Medical News Today, Nov 15, 2018
[8] 黃叔牧,"癌症的化學治療."高醫醫訊, vol. 17, no. 5, 1997
[9] D. M. Pardoll, "The blockade of immune checkpoints in cancer immunotherapy". Nature Reviews. Cancer, vol. 12, no.4, pp.252-264, 2012.
[10] C. Granier, E. De Guillebon, C. Blanc , H. Roussel, C. Badoual, E. Colin, A. Saldmann, A. Gey, S. Oudard, and E. Tartour, "Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer," ESMO open, vol. 2, no. 2, p. e000213, 2017.
[11] S. L. Topalian, C. G. Drake, and D. M. Pardoll, "Immune checkpoint blockade: a common denominator approach to cancer therapy," Cancer cell, vol. 27, no. 4, pp. 450-461, 2015.
[12] M. J. Smyth, Y. Hayakawa, K. Takeda, and H. Yagita, "New aspects of natural-killer-cell surveillance and therapy of cancer," Nature Reviews Cancer, vol. 2, no. 11, p. 850, 2002.
[13] J. Buechner, S. A. Grupp, S. L. Maude, M. Boyer, H. Bittencourt, T. W. Laetsch, Peter Bader, M. R. Verneris, H. Stefanski, G. D. Myers, M. Qayed, M. A. Pulsipher, B. De Moerloose, H Hiramatsu, K. Schlis, K. Davis,and P. L. Martin, E. Nemecek, C. Peters, P. Wood, T. Taran, K. T. Mueller, Y. Zhang, and S. Rives, "Global registration trial of efficacy and safety of CTL019 in pediatric and young adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): update to the interim analysis," Clinical Lymphoma, Myeloma and Leukemia, vol. 17, pp. S263-S264, 2017.
[14] L. Rosenbaum, "Tragedy, perseverance, and chance—the story of CAR-T therapy," New England Journal of Medicine, vol. 377, no. 14, pp. 1313-1315, 2017.
[15] N. M. Hossain, S. Dahiya, R. Le, A. M. Abramian, K. A. Kong, L. S. Muffly, and D. B. Miklos, "Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy," Leukemia & lymphoma, pp. 1-4, 2018.
[16] S. Boyden, "The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes," J Exp Med, vol. 115, pp. 453-66, Mar 1, 1962.
[17] D. Zicha, G. A. Dunn, and A. F. Brown, "A new direct-viewing chemotaxis chamber," J Cell Sci, vol. 99 ( Pt 4), pp. 769-75, Aug 1991.
[18] S. H. Zigmond and J. G. Hirsch, "Leukocyte locomotion and chemotaxis. New methods for evaluation, and demonstration of a cell-derived chemotactic factor," J Exp Med, vol. 137, no. 2, pp. 387-410, Feb 1, 1973.
[19] M. Kim and T. Kim, "Diffusion-Based and Long-Range Concentration Gradients of Multiple Chemicals for Bacterial Chemotaxis Assays," Analytical Chemistry, vol. 82, no. 22, pp. 9401-9409, 2010/11/15, 2010.
[20] K. Francis and B. O. Palsson, "Effective intercellular communication distances are determined by the relative time constants for cyto/chemokine secretion and diffusion," Proc Natl Acad Sci U S A, vol. 94, no. 23, pp. 12258-62, Nov 11 1997.
[21] T. M. Keenan and A. Folch, "Biomolecular gradients in cell culture systems," Lab Chip, vol. 8, no. 1, pp. 34-57, Jan 2008.
[22] S. Toetsch, P. Olwell, A. Prina-Mello, and Y. Volkov, "The evolution of chemotaxis assays from static models to physiologically relevant platforms," Integr Biol (Camb), vol. 1, no. 2, pp. 170-81, Feb 2009.
[23] B. G. Chung and J. Choo, "Microfluidic gradient platforms for controlling cellular behavior," Electrophoresis, vol. 31, no. 18, pp. 3014-27, Sep 2010.
[24] K. Gupta, D.H.Kim, D. Ellison, C. Smith, A Kundu, J Tuan, K. Y. Suh,and A. Levchenko, "Lab-on-a-chip devices as an emerging platform for stem cell biology," Lab Chip, vol. 10, no. 16, pp. 2019-31, Aug 21, 2010.
[25] N. Li Jeon, H. Baskaran, S. K. Dertinger, G. M. Whitesides, L. Van de Water, and M. Toner, "Neutrophil chemotaxis in linear and complex gradients of interleukin-8 formed in a microfabricated device," Nat Biotechnol, vol. 20, no. 8, pp. 826-30, Aug 2002.
[26] P. J. Hung, P. J. Lee, P. Sabounchi, R. Lin, and L. P. Lee, "Continuous perfusion microfluidic cell culture array for high-throughput cell-based assays," Biotechnol Bioeng, vol. 89, no. 1, pp. 1-8, Jan 5, 2005.
[27] P. J. Lee, P. J. Hung, V. M. Rao, and L. P. Lee, "Nanoliter scale microbioreactor array for quantitative cell biology," Biotechnol Bioeng, vol. 94, no. 1, pp. 5-14, May 5, 2006.
[28] T. I. Moore, C. S. Chou, Q. Nie, N. L. Jeon, and T. M. Yi, "Robust spatial sensing of mating pheromone gradients by yeast cells," PLoS One, vol. 3, no. 12, p. e3865, 2008.
[29] C. L. Walsh, B. M. Babin, R. W. Kasinskas, J. A. Foster, M. J. McGarry, and N. S. Forbes, "A multipurpose microfluidic device designed to mimic microenvironment gradients and develop targeted cancer therapeutics," Lab Chip, vol. 9, no. 4, pp. 545-54, Feb 21, 2009.
[30] J. Atencia, G. A. Cooksey, and L. E. Locascio, "A robust diffusion-based gradient generator for dynamic cell assays," Lab Chip, vol. 12, no. 2, pp. 309-16, Jan 21, 2012.
[31] D. Irimia, G. Charras, N. Agrawal, T. Mitchison, and M. Toner, "Polar stimulation and constrained cell migration in microfluidic channels," Lab Chip, vol. 7, no. 12, pp. 1783-90, Dec 2007.
[32] G. M. Walker, H. C. Zeringue, and D. J. Beebe, "Microenvironment design considerations for cellular scale studies," Lab Chip, vol. 4, no. 2, pp. 91-7, Apr 2004.
[33] T. Ahmed, T. S. Shimizu, and R. Stocker, "Bacterial chemotaxis in linear and nonlinear steady microfluidic gradients," Nano Lett, vol. 10, no. 9, pp. 3379-85, Sep 8, 2010.
[34] C. R. Kothapalli E. van Veen, S. de Valence, S Chung, I. K. Zervantonakis, F. B. Gertler, and R. D. Kamm, "A high-throughput microfluidic assay to study neurite response to growth factor gradients," Lab Chip, vol. 11, no. 3, pp. 497-507, Feb 7, 2011.
[35] V. Mengeaud, J. Josserand, and H. H. Girault, "Mixing processes in a zigzag microchannel: Finite element simulations and optical study," Analytical Chemistry, vol. 74, no. 16, pp. 4279-4286, Aug 15, 2002.
[36] Y. C. Toh, C. Zhang, J. Zhang, Y. M. Khong, S. Chang, V. D. Samper, D. van Noort, D. W. Hutmacher , and H. Yu, "A novel 3D mammalian cell perfusion-culture system in microfluidic channels," Lab on a Chip, vol. 7, no. 3, pp. 302-309, 2007.
[37] Y. C. Toh, T. C. Lim, D. Tai, G. F. Xiao, D. van Noort, and H. R. Yu, "A microfluidic 3D hepatocyte chip for drug toxicity testing," Lab on a Chip, vol. 9, no. 14, pp. 2026-2035, 2009.
[38] V. L. Tsang, A. A. Chen, L. M. Cho,K. D. Jadin,R. L. Sah,S. DeLong, J. L. West, and S. N. Bhatia, "Fabrication of 3D hepatic tissues by additive photopatterning of cellular hydrogels," Faseb Journal, vol. 21, no. 3, pp. 790-801, Mar 2007.
[39] G. H. Underhill, A. A. Chen, D. R. Albrecht, and S. N. Bhatia, "Assessment of hepatocellular function within PEG hydrogels," Biomaterials, vol. 28, no. 2, pp. 256-270, Jan 2007.
[40] V. Chan, P. Zorlutuna, J. H. Jeong, H. Kong, and R. Bashir, "Three-dimensional photopatterning of hydrogels using stereolithography for long-term cell encapsulation," Lab on a Chip, vol. 10, no. 16, pp. 2062-2070, 2010.
[41] J. W. Nichol, S. T. Koshy, H. Bae, C. M. Hwang, S. Yamanlar, and A. Khademhosseini, "Cell-laden microengineered gelatin methacrylate hydrogels," Biomaterials, vol. 31, no. 21, pp. 5536-5544, 2010.
[42] M. S. Kim, H. Hwang, Y.-S. Choi, and J.-K. Park, "Microfluidic micropillar arrays for 3D cell culture," The Open Biotechnology Journal, vol. 2, pp. 224-228, 2008.
[43] P. C. Tumeh,Christina L. Harview, Jennifer H. Yearley, I. Peter Shintaku, Emma J. M. Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu, Alisha N. West, Manuel Carmona, Christine Kivork, Elizabeth Seja, Grace Cherry, Antonio Gutierrez, Tristan R. Grogan, Christine Mateus, Gorana Tomasic, John A. Glaspy, Ryan O. Emerson, Harlan Robins, Robert H. Pierce3, David A. Elashoff, Caroline Robert, and Antoni Ribas "PD-1 blockade induces responses by inhibiting adaptive immune resistance," Nature, vol. 515, no. 7528, p. 568, 2014.